$129 Million is the total value of Foresite Capital Management V, LLC's 11 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HIMS | Buy | Hims & Hers Health, Inc. | $25,905,265 | +39.8% | 4,041,383 | +21.7% | 20.12% | +41.3% |
| Buy | Theseus Pharmaceuticals, Inc. | $17,855,023 | -7.7% | 3,585,346 | +7.5% | 13.87% | -6.8% | |
| Buy | Pardes Biosciences Inc | $16,964,110 | -2.5% | 10,037,935 | +6.8% | 13.18% | -1.5% | |
| New | Disc Medicine, Inc. | $4,843,454 | – | 243,513 | +100.0% | 3.76% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 25.8% |
| Hims & Hers Health, Inc. | 11 | Q3 2023 | 37.5% |
| Aclaris Therapeutics, Inc. | 11 | Q3 2023 | 15.4% |
| Pharvaris N.V. | 11 | Q3 2023 | 5.5% |
| Quantum-Si Incorporated | 9 | Q2 2023 | 11.3% |
| TheseusPharmaceuticals, Inc. | 8 | Q3 2023 | 24.4% |
| Somalogic, Inc. | 8 | Q2 2023 | 20.5% |
| Compass Therapeutics, Inc. | 8 | Q3 2023 | 17.2% |
| Pardes Biosciences Inc | 7 | Q2 2023 | 37.8% |
| Gemini Therapeutics, Inc. | 7 | Q3 2022 | 9.7% |
View Foresite Capital Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-08-31 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-07-19 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
View Foresite Capital Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.